http://preview.vandria.com/wp-content/uploads/2025/11/Vandria-Logo-RGB-Color.svg00Webadnhttp://preview.vandria.com/wp-content/uploads/2025/11/Vandria-Logo-RGB-Color.svgWebadn2025-12-02 08:00:062025-12-02 08:00:06Vandria Reports Positive Phase 1 Target Engagement Data for VNA-318, Supporting Further Development in Alzheimer’s Disease
http://preview.vandria.com/wp-content/uploads/2025/11/Vandria-Logo-RGB-Color.svg00Webadnhttp://preview.vandria.com/wp-content/uploads/2025/11/Vandria-Logo-RGB-Color.svgWebadn2024-12-18 08:00:132025-11-28 09:39:32Vandria announces first subjects dosed in its first-in-human Phase 1 clinical trial of VNA-318 brain-penetrant mitophagy inducer
http://preview.vandria.com/wp-content/uploads/2025/11/Vandria-Logo-RGB-Color.svg00Webadnhttp://preview.vandria.com/wp-content/uploads/2025/11/Vandria-Logo-RGB-Color.svgWebadn2024-08-21 08:00:442025-11-18 10:19:14Hevolution Foundation and Dolby Family Ventures join Vandria’s 2nd Series A closing, bringing the total round to $30.7M (CHF 28.3M) to Progress the Mitophagy Inducer VNA-318 into CNS Clinical Development
http://preview.vandria.com/wp-content/uploads/2025/11/Vandria-Logo-RGB-Color.svg00Webadnhttp://preview.vandria.com/wp-content/uploads/2025/11/Vandria-Logo-RGB-Color.svgWebadn2024-02-08 08:00:392025-11-18 10:19:19Vandria Awarded €3.8M in Prestigious Innosuisse and Eurostars Grants to Advance Innovative Drug Programs for Age-Related Diseases of the CNS and Muscle
http://preview.vandria.com/wp-content/uploads/2025/11/Vandria-Logo-RGB-Color.svg00Webadnhttp://preview.vandria.com/wp-content/uploads/2025/11/Vandria-Logo-RGB-Color.svgWebadn2023-12-14 08:00:442025-11-19 13:14:59Vandria Announces $20.6M (CHF18M) Series A Financing Led by ND Capital to Drive CNS Clinical Program and Mitochondrial Therapeutics Platform
